Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05101187 · ClinicalTrials.gov registry record · Phase 3
Olorofim Aspergillus Infection Study
A Phase 3 study of Invasive Aspergillosis, sponsored by F2G Biotech.
- Active
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
- 20
- Study locations
NCT05101187 is a Phase 3 study of Invasive Aspergillosis that is active but no longer recruiting, run by F2G Biotech. The registered enrollment target is 225 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT05101187, a Phase 3 study of Invasive Aspergillosis, is active but no longer recruiting, sponsored by F2G Biotech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).
Conditions Studied
Interventions
- DRUG Olorofim
- DRUG AmBisome®
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- University of California Davis Health System - Sacramento
- UCSF Helen Diller Medical Center at Parnassus Heights - San Francisco
Maryland
- The Johns Hopkins Hospital - Baltimore
- NIH Clinical Center ,NIAID,NIH - Bethesda
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic - Rochester - Rochester
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Duke Department of Medicine Infectious Diseases Division - Durham
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- University of Florida - Gainesville
Georgia
- Augusta University - Augusta
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2026-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05101187
The ClinicalTrials.gov registry entry for NCT05101187 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is F2G Biotech, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Invasive Aspergillosis appearing as the primary indexed condition, and to 2 interventions - of which Olorofim is the first listed.
NCT05101187 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Maryland, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05101187 about?
NCT05101187 is a clinical study titled "Olorofim Aspergillus Infection Study". The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).
What is the current status of trial NCT05101187?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2022-03-31. Estimated completion is 2026-11-01.
What conditions does trial NCT05101187 study?
This clinical trial studies the following conditions: Invasive Aspergillosis.
What interventions are being tested in trial NCT05101187?
The interventions under investigation include: Olorofim (DRUG), AmBisome® (DRUG).
Who is sponsoring clinical trial NCT05101187?
This trial is sponsored by F2G Biotech, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05101187 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Aspergillosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.